Compare TENB & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TENB | IMNM |
|---|---|---|
| Founded | 2002 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.5B |
| IPO Year | 2018 | 2020 |
| Metric | TENB | IMNM |
|---|---|---|
| Price | $33.50 | $21.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 10 |
| Target Price | $31.69 | ★ $32.80 |
| AVG Volume (30 Days) | ★ 5.3M | 975.9K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.23 | ★ 51.40 |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $999,405,000.00 | $6,941,000.00 |
| Revenue This Year | $9.37 | N/A |
| Revenue Next Year | $7.04 | $1,127.34 |
| P/E Ratio | $717.60 | ★ N/A |
| Revenue Growth | ★ 11.04 | N/A |
| 52 Week Low | $15.73 | $11.09 |
| 52 Week High | $43.67 | $30.06 |
| Indicator | TENB | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 45.87 | 31.21 |
| Support Level | $30.97 | $19.39 |
| Resistance Level | $39.26 | $23.25 |
| Average True Range (ATR) | 2.20 | 1.19 |
| MACD | 0.03 | -0.42 |
| Stochastic Oscillator | 44.39 | 1.42 |
Founded in 2002, Tenable is a cybersecurity company that began providing vulnerability management solutions under its Nessus software. In recent years, Tenable has expanded its portfolio to provide a broader range of exposure management modules. Solutions include cloud security and compliance, active directory management, operational technology security and advanced vulnerability analytics. The Maryland-based company went public in 2018.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.